Preoperative HALP score is a prognostic factor for intrahepatic cholangiocarcinoma patients undergoing curative hepatic resection: association with sarcopenia and immune microenvironment.
Hemoglobin, albumin, lymphocyte, and platelet (HALP) score
Immune microenvironment
Intrahepatic cholangiocarcinoma
Sarcopenia
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
19
02
2023
accepted:
18
05
2023
medline:
23
10
2023
pubmed:
29
5
2023
entrez:
29
5
2023
Statut:
ppublish
Résumé
The hemoglobin-albumin-lymphocyte-platelet (HALP) score is a combination index that assesses nutritional status and systemic inflammatory response and is reported to predict prognosis in several cancer types. However, researches about the usefulness of the HALP score in intrahepatic cholangiocarcinoma (ICC) are limited. This was a single-center, retrospective study of 95 patients who underwent surgical resection for ICC between 1998 and 2018. We divided patients into two groups by calculating the cutoff value of the HALP score and examined clinicopathological characteristics, prognosis, and sarcopenia. Tumor-infiltrating lymphocytes (TILs), CD8 + TILs, and FOXP3 + TILs were evaluated by immunohistochemical staining of resected tumors. Of 95 patients, 22 were HALP-low. The HALP-low group had significantly lower hemoglobin (p = 0.0007), lower albumin (p = 0.0013), higher platelet counts (p < 0.0001), fewer lymphocytes (p < 0.0001), higher CA19-9 levels (p = 0.0431), and more lymph node metastasis (p = 0.0013). Multivariate analysis revealed that the independent prognostic factors for disease-free survival were maximum tumor size (≥ 5.0 cm) (p = 0.0033), microvascular invasion (p = 0.0108), and HALP score (≤ 25.2) (p = 0.0349), and that factors for overall survival were lymph node metastasis (p = 0.0020) and HALP score (≤ 25.2) (p = 0.0014). The HALP-low group contained significantly more patients with sarcopenia (p = 0.0015). Immunohistochemistry showed that counts of CD8 + TILs were significantly lower in the HALP-low group (p = 0.0075). We demonstrated that low HALP score is an independent prognostic factor for ICC patients undergoing curative hepatic resection and is associated with sarcopenia and the immune microenvironment.
Sections du résumé
BACKGROUND
BACKGROUND
The hemoglobin-albumin-lymphocyte-platelet (HALP) score is a combination index that assesses nutritional status and systemic inflammatory response and is reported to predict prognosis in several cancer types. However, researches about the usefulness of the HALP score in intrahepatic cholangiocarcinoma (ICC) are limited.
METHODS
METHODS
This was a single-center, retrospective study of 95 patients who underwent surgical resection for ICC between 1998 and 2018. We divided patients into two groups by calculating the cutoff value of the HALP score and examined clinicopathological characteristics, prognosis, and sarcopenia. Tumor-infiltrating lymphocytes (TILs), CD8 + TILs, and FOXP3 + TILs were evaluated by immunohistochemical staining of resected tumors.
RESULTS
RESULTS
Of 95 patients, 22 were HALP-low. The HALP-low group had significantly lower hemoglobin (p = 0.0007), lower albumin (p = 0.0013), higher platelet counts (p < 0.0001), fewer lymphocytes (p < 0.0001), higher CA19-9 levels (p = 0.0431), and more lymph node metastasis (p = 0.0013). Multivariate analysis revealed that the independent prognostic factors for disease-free survival were maximum tumor size (≥ 5.0 cm) (p = 0.0033), microvascular invasion (p = 0.0108), and HALP score (≤ 25.2) (p = 0.0349), and that factors for overall survival were lymph node metastasis (p = 0.0020) and HALP score (≤ 25.2) (p = 0.0014). The HALP-low group contained significantly more patients with sarcopenia (p = 0.0015). Immunohistochemistry showed that counts of CD8 + TILs were significantly lower in the HALP-low group (p = 0.0075).
CONCLUSIONS
CONCLUSIONS
We demonstrated that low HALP score is an independent prognostic factor for ICC patients undergoing curative hepatic resection and is associated with sarcopenia and the immune microenvironment.
Identifiants
pubmed: 37247134
doi: 10.1007/s10147-023-02358-2
pii: 10.1007/s10147-023-02358-2
doi:
Substances chimiques
Albumins
0
Hemoglobins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1082-1091Subventions
Organisme : Japan Society for the Promotion of Science
ID : JP-19K09198
Organisme : The Japan Medical Association
ID : Medical Research Encouragement Prize
Informations de copyright
© 2023. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.
Références
Banales JM, Marin JJG, Lamarca A et al (2020) Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroentero 17:557–588. https://doi.org/10.1038/s41575-020-0310-z
doi: 10.1038/s41575-020-0310-z
Khan SA, Davidson BR, Goldin RD et al (2012) Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut 61:1657. https://doi.org/10.1136/gutjnl-2011-301748
doi: 10.1136/gutjnl-2011-301748
pubmed: 22895392
Hosoda K, Shimizu A, Kubota K et al (2022) Usefulness of frailty to predict short- and long-term outcomes in patients who have undergone major hepatectomy for perihilar cholangiocarcinoma. Ann Gastroenterological Surg 6:833–841. https://doi.org/10.1002/ags3.12596
doi: 10.1002/ags3.12596
Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. New Engl J Medicine 362:1273–1281. https://doi.org/10.1056/nejmoa0908721
doi: 10.1056/nejmoa0908721
Lowery MA, Ptashkin R, Jordan E et al (2018) Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin Cancer Res 24:4154–4161. https://doi.org/10.1158/1078-0432.ccr-18-0078
doi: 10.1158/1078-0432.ccr-18-0078
pubmed: 29848569
pmcid: 6642361
Yugawa K, Itoh S, Yoshizumi T et al (2021) Lymphocyte–C-reactive protein ratio as a prognostic marker associated with the tumor immune microenvironment in intrahepatic cholangiocarcinoma. Int J Clin Oncol 26:1901–1910. https://doi.org/10.1007/s10147-021-01962-4
doi: 10.1007/s10147-021-01962-4
pubmed: 34117554
Yugawa K, Itoh S, Iseda N et al (2021) Obesity is a risk factor for intrahepatic cholangiocarcinoma progression associated with alterations of metabolic activity and immune status. Sci Rep-uk 11:5845. https://doi.org/10.1038/s41598-021-85186-6
doi: 10.1038/s41598-021-85186-6
Yugawa K, Itoh S, Kurihara T et al (2018) Skeletal muscle mass predicts the prognosis of patients with intrahepatic cholangiocarcinoma. Am J Surg 218:952–958. https://doi.org/10.1016/j.amjsurg.2019.03.010
doi: 10.1016/j.amjsurg.2019.03.010
Jiang H, Li H, Li A et al (2016) Preoperative combined hemoglobin, albumin, lymphocyte and platelet levels predict survival in patients with locally advanced colorectal cancer. Oncotarget 7:72076–72083. https://doi.org/10.18632/oncotarget.12271
doi: 10.18632/oncotarget.12271
pubmed: 27765916
pmcid: 5342146
Peng D, Zhang C, Gong Y et al (2018) Prognostic significance of HALP (hemoglobin, albumin, lymphocyte and platelet) in patients with bladder cancer after radical cystectomy. Sci Rep-uk 8:794. https://doi.org/10.1038/s41598-018-19146-y
doi: 10.1038/s41598-018-19146-y
Zhang D, Zeng H, Pan Y et al (2022) Liver tumor markers, HALP Score, and NLR: simple, cost-effective, easily accessible indexes for predicting prognosis in ICC patients after surgery. J Personal Med 12:2041. https://doi.org/10.3390/jpm12122041
doi: 10.3390/jpm12122041
Itoh S, Shirabe K, Taketomi A et al (2012) Zero mortality in more than 300 hepatic resections: validity of preoperative volumetric analysis. Surg Today 42:435–440. https://doi.org/10.1007/s00595-011-0108-2
doi: 10.1007/s00595-011-0108-2
pubmed: 22200757
Itoh S, Tomiyama T, Morinaga A et al (2022) Clinical effects of the use of the indocyanine green fluorescence imaging technique in laparoscopic partial liver resection. Ann Gastroenterological Surg 6:688–694. https://doi.org/10.1002/ags3.12563
doi: 10.1002/ags3.12563
Itoh S, Tsujita E, Fukuzawa K et al (2021) Prognostic significance of preoperative PNI and CA19-9 for pancreatic ductal adenocarcinoma: a multi-institutional retrospective study. Pancreatology 21:1356–1363. https://doi.org/10.1016/j.pan.2021.08.003
doi: 10.1016/j.pan.2021.08.003
pubmed: 34426076
Toshida K, Itoh S, Tomiyama T et al (2022) Comparison of the prognostic effect of sarcopenia on atezolizumab plus bevacizumab and lenvatinib therapy in hepatocellular carcinoma patients. Jgh Open 6:477–486. https://doi.org/10.1002/jgh3.12777
doi: 10.1002/jgh3.12777
pubmed: 35822124
pmcid: 9260215
Hendry S, Salgado R, Gevaert T et al (2017) Assessing tumor-infiltrating lymphocytes in solid tumors. Adv Anat Pathol 24:311–335. https://doi.org/10.1097/pap.0000000000000161
doi: 10.1097/pap.0000000000000161
pubmed: 28777143
pmcid: 5638696
Itoh S, Yoshizumi T, Kitamura Y et al (2021) Impact of metabolic activity in hepatocellular carcinoma: association with immune status and vascular formation. Hepatology Commun 5:1278–1289. https://doi.org/10.1002/hep4.1715
doi: 10.1002/hep4.1715
Itoh S, Yoshizumi T, Yugawa K et al (2020) Impact of immune response on outcomes in hepatocellular carcinoma: association with vascular formation. Hepatology 72:1987–1999. https://doi.org/10.1002/hep.31206
doi: 10.1002/hep.31206
pubmed: 32112577
Madeddu C, Gramignano G, Astara G et al (2018) Pathogenesis and treatment options of cancer related anemia: perspective for a targeted mechanism-based approach. Front Physiol 9:1294. https://doi.org/10.3389/fphys.2018.01294
doi: 10.3389/fphys.2018.01294
pubmed: 30294279
pmcid: 6159745
Matsumoto T, Itoh S, Yoshizumi T et al (2020) C-reactive protein : albumin ratio in patients with resectable intrahepatic cholangiocarcinoma. Bjs Open 4:1146–1152. https://doi.org/10.1002/bjs5.50348
doi: 10.1002/bjs5.50348
pubmed: 32959537
pmcid: 7709369
Hu G, Liu Q, Ma J et al (2018) Prognostic significance of platelet-to-lymphocyte ratio in cholangiocarcinoma: a meta-analysis. Biomed Res Int 2018:7375169. https://doi.org/10.1155/2018/7375169
doi: 10.1155/2018/7375169
pubmed: 30539019
pmcid: 6261069
Mano Y, Yoshizumi T, Yugawa K et al (2018) Lymphocyte-to-monocyte ratio is a predictor of survival after liver transplantation for hepatocellular carcinoma. Liver Transplant 24:1603–1611. https://doi.org/10.1002/lt.25204
doi: 10.1002/lt.25204
Iseda N, Itoh S, Yoshizumi T et al (2021) Lymphocyte-to-C-reactive protein ratio as a prognostic factor for hepatocellular carcinoma. Int J Clin Oncol 26:1890–1900. https://doi.org/10.1007/s10147-021-01985-x
doi: 10.1007/s10147-021-01985-x
pubmed: 34251555
Miyazaki K, Morine Y, Imura S et al (2021) Preoperative lymphocyte/C-reactive protein ratio and its correlation with CD8+ tumor-infiltrating lymphocytes as a predictor of prognosis after resection of intrahepatic cholangiocarcinoma. Surg Today 51:1985–1995. https://doi.org/10.1007/s00595-021-02295-5
doi: 10.1007/s00595-021-02295-5
pubmed: 34009433
Furukawa K, Haruki K, Taniai T et al (2021) Osteosarcopenia is a potential predictor for the prognosis of patients who underwent hepatic resection for colorectal liver metastases. Ann Gastroenterological Surg 5:390–398. https://doi.org/10.1002/ags3.12428
doi: 10.1002/ags3.12428
Feliciano EMC, Kroenke CH, Meyerhardt JA et al (2017) Association of systemic inflammation and sarcopenia with survival in nonmetastatic colorectal cancer: results from the C SCANS study. Jama Oncol 3:e172319–e172319. https://doi.org/10.1001/jamaoncol.2017.2319
doi: 10.1001/jamaoncol.2017.2319
pubmed: 28796857
Kitano Y, Yamashita Y, Saito Y et al (2019) Sarcopenia affects systemic and local immune system and impacts postoperative outcome in patients with extrahepatic cholangiocarcinoma. World J Surg 43:2271–2280. https://doi.org/10.1007/s00268-019-05013-y
doi: 10.1007/s00268-019-05013-y
pubmed: 31041559
Xu S-S, Li S, Xu H-X et al (2020) Haemoglobin, albumin, lymphocyte and platelet predicts postoperative survival in pancreatic cancer. World J Gastroentero 26:828–838. https://doi.org/10.3748/wjg.v26.i8.828
doi: 10.3748/wjg.v26.i8.828
Welzel TM, Graubard BI, El–Serag HB et al (2007) Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol H 5:1221–1228. https://doi.org/10.1016/j.cgh.2007.05.020
doi: 10.1016/j.cgh.2007.05.020
Michelotti GA, Machado MV, Diehl AM (2013) NAFLD, NASH and liver cancer. Nat Rev Gastroentero 10:656–665. https://doi.org/10.1038/nrgastro.2013.183
doi: 10.1038/nrgastro.2013.183
Ginès P, Krag A, Abraldes JG et al (2021) Liver cirrhosis. Lancet 398:1359–1376. https://doi.org/10.1016/s0140-6736(21)01374-x
doi: 10.1016/s0140-6736(21)01374-x
pubmed: 34543610
Traub J, Reiss L, Aliwa B et al (2021) Malnutrition in patients with liver cirrhosis. Nutrients 13:540. https://doi.org/10.3390/nu13020540
doi: 10.3390/nu13020540
pubmed: 33562292
pmcid: 7915767